PL360900A1 - Niskohigroskopijna substancja lecznicza na bazie aripiprazolu i sposoby jej wytwarzania - Google Patents

Niskohigroskopijna substancja lecznicza na bazie aripiprazolu i sposoby jej wytwarzania

Info

Publication number
PL360900A1
PL360900A1 PL02360900A PL36090002A PL360900A1 PL 360900 A1 PL360900 A1 PL 360900A1 PL 02360900 A PL02360900 A PL 02360900A PL 36090002 A PL36090002 A PL 36090002A PL 360900 A1 PL360900 A1 PL 360900A1
Authority
PL
Poland
Prior art keywords
processes
preparation
drug substance
low hygroscopic
aripiprazole drug
Prior art date
Application number
PL02360900A
Other languages
English (en)
Other versions
PL225415B1 (pl
Inventor
Takuji Bando
Satoshi Aoki
Junichi Kawasaki
Makoto Ishigami
Youichi Taniguchi
Tsuyoshi Yabuuchi
Kiyoshi Fujimoto
Yoshihiro Nishioka
Noriyuki Kobayashi
Tsutomu Fujimura
Masanori Takahashi
Kaoru Abe
Tomonori Nakagawa
Koichi Shinhama
Naoto Utsumi
Michiaki Tominaga
Yoshihiro Oi
Shohei Yamada
Kenji Tomikawa
Original Assignee
Otsuka Pharmaceutical Co,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27171631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL360900(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Application filed by Otsuka Pharmaceutical Co,Ltd. filed Critical Otsuka Pharmaceutical Co,Ltd.
Publication of PL360900A1 publication Critical patent/PL360900A1/pl
Publication of PL225415B1 publication Critical patent/PL225415B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
PL360900A 2001-09-25 2002-09-25 Kryształy B bezwodnego aripiprazolu i sposób ich wytwarzania, kompozycja farmaceutyczna, farmaceutyczny stały preparat doustny i sposób jego wytwarzania PL225415B1 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2001-290645 2001-09-25
JP2001290645 2001-09-25
JP2001348276 2001-11-14
JP2001-348276 2001-11-14
CA2379005 2002-03-27
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
PCT/JP2002/009858 WO2003026659A1 (en) 2001-09-25 2002-09-25 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
PL360900A1 true PL360900A1 (pl) 2004-09-20
PL225415B1 PL225415B1 (pl) 2017-04-28

Family

ID=27171631

Family Applications (1)

Application Number Title Priority Date Filing Date
PL360900A PL225415B1 (pl) 2001-09-25 2002-09-25 Kryształy B bezwodnego aripiprazolu i sposób ich wytwarzania, kompozycja farmaceutyczna, farmaceutyczny stały preparat doustny i sposób jego wytwarzania

Country Status (23)

Country Link
US (20) US20040058935A1 (pl)
EP (6) EP1419776B2 (pl)
JP (3) JP3760264B2 (pl)
CN (16) CN101792415A (pl)
AR (2) AR033485A1 (pl)
AT (5) ATE467416T1 (pl)
AU (1) AU2002334413C1 (pl)
BR (1) BR0205391A (pl)
CA (6) CA2689052C (pl)
CY (1) CY1118195T1 (pl)
DE (5) DE60235995D1 (pl)
DK (5) DK1927356T3 (pl)
ES (5) ES2343602T3 (pl)
HU (1) HUP0600141A3 (pl)
IL (3) IL153838A0 (pl)
MX (1) MXPA03000440A (pl)
NO (7) NO328134B1 (pl)
PE (1) PE20090124A1 (pl)
PL (1) PL225415B1 (pl)
PT (5) PT1927357E (pl)
SI (4) SI1927356T1 (pl)
UA (1) UA84764C2 (pl)
WO (1) WO2003026659A1 (pl)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
GEP20063996B (en) * 2002-08-20 2006-12-11 Bristol Myers Squibb Co Aripiprazole complex formulation and use thereof
AU2003291757A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
RU2356554C2 (ru) 2002-12-27 2009-05-27 Оцука Фармасьютикал Ко., Лтд. Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1480953B2 (en) † 2003-01-09 2010-08-18 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
EP1618103A2 (en) * 2003-04-25 2006-01-25 Cadila Healthcare Ltd. Polymorphs of aripiprazole
US9125939B2 (en) * 2003-05-23 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
AU2003259545A1 (en) * 2003-07-25 2005-02-14 Hetero Drugs Limited Aripiprazole crystalline forms
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
KR100931784B1 (ko) 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
US7504504B2 (en) * 2003-12-16 2009-03-17 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
CN1914176A (zh) 2004-02-05 2007-02-14 特瓦制药工业有限公司 制备阿立哌唑的方法
DE202005020539U1 (de) * 2004-02-05 2006-09-28 Teva Pharmaceutical Industries Ltd. Aripiprazol
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2006030446A1 (en) * 2004-09-13 2006-03-23 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
KR101041551B1 (ko) 2004-10-08 2011-06-15 수벤 라이프 사이언시스 리미티드 아리피프라졸 제조를 위해 유용한 신규 중간체와 신규중간체 및 아리피프라졸 제조 방법
CN100338038C (zh) * 2004-10-14 2007-09-19 重庆医药工业研究院有限责任公司 阿立派唑的新晶型及其制备方法
CN101087760B (zh) * 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
WO2006053781A1 (en) * 2004-11-18 2006-05-26 Synthon B.V. Process of making crystalline aripiprazole
EP1686117A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Polymorph and solvates of aripiprazole
CA2594690C (en) 2005-01-27 2013-08-27 Sandoz Ag Salts of aripiprazole
ES2526415T3 (es) 2005-03-17 2015-01-12 Synthon B.V. Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
WO2006097343A1 (en) † 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline type ii aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2007004061A1 (en) * 2005-04-15 2007-01-11 Medichem, S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
CN100432053C (zh) * 2005-06-07 2008-11-12 上海医药工业研究院 阿立哌唑晶型及其制备方法
HUP0500683A3 (en) * 2005-07-14 2009-03-30 Egis Gyogyszergyar Nyilvanosan New arylpiprazole salts for producing pharmaceutical composition
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
EP1793801A1 (en) * 2005-07-15 2007-06-13 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
JP2008521835A (ja) 2005-09-29 2008-06-26 テバ ファーマシューティカル インダストリーズ リミティド 無水アリピプラゾールフォームｉｉの調製方法
CZ299485B6 (cs) * 2005-10-11 2008-08-13 Zentiva, A. S. Zpusob výroby aripiprazolu
JP2008537540A (ja) * 2005-12-22 2008-09-18 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールの粒径を小さくする方法
DE602006004694D1 (de) * 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
CN101351193A (zh) * 2006-01-05 2009-01-21 特瓦制药工业有限公司 阿立哌唑的干法制剂
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
EP1880714A1 (en) 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
TR200604349A2 (tr) 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2008059518A2 (en) * 2006-09-28 2008-05-22 Cadila Healthcare Limited Process for preparing crystalline aripiprazole
WO2008051541A2 (en) * 2006-10-24 2008-05-02 Cambrex Charles City, Inc. Process for preparing anhydrous aripirazole type i
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CA2691597C (en) * 2007-06-25 2016-04-05 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
ATE482691T1 (de) * 2008-01-23 2010-10-15 Helm Ag Amorphes aripiprazol und verfahren zu seiner herstellung
WO2010079506A2 (en) 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of aripiprazole
EP2233471A1 (en) 2009-02-06 2010-09-29 Adamed Sp. z o.o. A salt of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-quinolinone with 5-sulfosalicylic acid and its preparation process
WO2010106551A2 (en) * 2009-03-09 2010-09-23 Neuland Laboratories Ltd. A process for the manufacture of pure anhydrous aripiprazole form b
EP2238976B1 (en) 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CA2773003A1 (en) 2009-09-15 2011-03-24 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
CN102372672B (zh) * 2010-08-24 2014-06-04 重庆圣华曦药业股份有限公司 低吸湿性阿立哌唑晶体iv、制备方法及其应用
CN101948426A (zh) * 2010-09-13 2011-01-19 浙江华海药业股份有限公司 一种制备阿立哌唑晶型b的新方法
JP2012121850A (ja) * 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
CN102060763B (zh) * 2010-12-27 2012-11-14 齐鲁制药有限公司 微粉型阿立哌唑晶型ⅰ或ⅱ的制备方法
MX358344B (es) 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
WO2012131451A1 (en) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Process for producing aripiprazole in anhydrous type i crystals
KR101340214B1 (ko) 2011-03-31 2013-12-10 주식회사 대웅제약 무수 아리피프라졸 ⅱ형 결정의 제조방법
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
JP6034377B2 (ja) * 2011-06-27 2016-11-30 シャンハイ チョンシ ファーマシューティカル コーポレイション アリピプラゾール医薬製剤及びその調製方法
TW201309651A (zh) * 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
CN103172563B (zh) * 2011-12-26 2015-03-25 北京京卫燕康药物研究所有限公司 小粒径的晶型i阿立哌唑的工业化制备
CN102584858B (zh) * 2011-12-31 2014-11-12 广州医药工业研究院 乳酸左旋尤利沙星晶体及其制备方法和用途
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
EP2827868B8 (en) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
US20150174247A1 (en) 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
KR101372840B1 (ko) * 2012-08-02 2014-03-12 주식회사 에스텍파마 무수 아리피프라졸 결정의 제조방법
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
JP2014114243A (ja) * 2012-12-11 2014-06-26 Ohara Yakuhin Kogyo Kk 安定な固形製剤の製造方法
CN104072416B (zh) * 2013-03-26 2017-06-20 江苏恩华药业股份有限公司 一种制备阿立哌唑结晶b的方法
ES2625613T3 (es) * 2013-04-30 2017-07-20 Otsuka Pharmaceutical Co., Ltd. Preparación sólida oral que comprende aripiprazol y método para producir una preparación sólida oral que comprende aripiprazol
AR096131A1 (es) * 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150093441A1 (en) * 2013-09-30 2015-04-02 Otsuka Pharmaceutical Co., Ltd Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
EP3065700A1 (en) 2013-11-07 2016-09-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
AU2015304148A1 (en) * 2014-08-18 2017-02-02 Samsung Electronics Co., Ltd. Antenna of electronic device
JP6591546B2 (ja) 2014-08-25 2019-10-16 アルカームス ファーマ アイルランド リミテッド 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス
JP6023770B2 (ja) * 2014-10-01 2016-11-09 株式会社パーマケム・アジア アリピプラゾール無水物ｂ形結晶の製造方法
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016138536A2 (en) * 2015-02-27 2016-09-01 Tactual Labs Co. Alterable ground plane for touch surfaces
EP3294724A4 (en) * 2015-05-08 2018-11-21 Davuluri, Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
JP6071083B2 (ja) * 2015-06-12 2017-02-01 大原薬品工業株式会社 安定性が改善された、アリピプラゾールを含有する散剤
JP2015172084A (ja) * 2015-07-06 2015-10-01 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
WO2017139971A1 (zh) * 2016-02-19 2017-08-24 诺瑞特国际药业股份有限公司 阿立哌唑的新晶型
TWI665194B (zh) * 2016-02-19 2019-07-11 諾瑞特國際藥業股份有限公司 阿立哌唑的新晶型
US20190070174A1 (en) * 2016-03-10 2019-03-07 The Regents Of The University Of Michigan Methods of treating neurodegenerative diseases
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
JP6572257B2 (ja) * 2017-05-16 2019-09-04 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
CN110128337A (zh) * 2019-06-10 2019-08-16 岳阳新华达制药有限公司 一种阿立哌唑晶型b的制备方法
KR102128883B1 (ko) 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법
CA3136727A1 (en) 2020-04-01 2021-10-07 Otsuka Pharmaceutical Co., Ltd. Methods of administering an arip-iprazole injectable preparation
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
KR20260004414A (ko) 2023-04-26 2026-01-08 오츠카 세이야쿠 가부시키가이샤 아리피프라졸을 사용하는 조현병 또는 양극성 장애 i형 치료를 위한 용량 개시
CN117309825B (zh) * 2023-11-30 2024-04-09 四川蜀道建筑科技有限公司 一种透光检测亚甲蓝mb值的设备
CN118878462B (zh) * 2024-06-12 2025-05-09 青岛科技大学 一种药物微晶水中制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62149664A (ja) 1978-03-30 1987-07-03 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体の製造法
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS55127371A (en) 1980-02-14 1980-10-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5162375A (en) * 1988-05-06 1992-11-10 Beecham Group P.L.C. Treatment of neuronal degeneration with 5HT1A agonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
ES2070151T3 (es) * 1988-08-10 1995-06-01 Otsuka Pharma Co Ltd Agentes cardiotonicos.
DE3831888A1 (de) 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
US5200410A (en) * 1988-09-20 1993-04-06 Troponwerke Gmbh & Co. Medicaments for the treatment of cerebral apoplexy
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5073377A (en) * 1988-11-03 1991-12-17 Miles Inc. Method of preparing oral dosage forms with a granulating composition
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
WO1992010200A1 (en) 1990-12-14 1992-06-25 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
CA2067475C (en) * 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
JP3155276B2 (ja) 1991-05-20 2001-04-09 ファルマシア・アンド・アップジョン・カンパニー カルボキサミド−（１，２ｎ）−カルボサイクリック−２−アミノテトラリン誘導体
DE4135551A1 (de) 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
US5292766A (en) 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
AU5446894A (en) 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2506547B2 (ja) 1993-06-16 1996-06-12 ミナミ産業株式会社 豆腐のパック詰め装置
JP2959615B2 (ja) 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH07247271A (ja) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
JP2987484B2 (ja) 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
JPH0940648A (ja) 1995-08-02 1997-02-10 Yamanouchi Pharmaceut Co Ltd 新規な８−（２−アミノアルコキシ）キノリン誘導体
US5766748A (en) 1995-11-30 1998-06-16 Mitsui Chemicals, Inc. Stretched film of lactic acid-based polymer
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
ATE236902T1 (de) 1996-05-07 2003-04-15 Pfizer Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
EP1014977A1 (en) 1996-08-22 2000-07-05 Glaxo Group Limited Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes
AU4091697A (en) 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
WO1999038864A1 (en) 1998-02-03 1999-08-05 American Home Products Corporation Oxazole derivatives as serotonin-1a receptor agonists
JP2001089128A (ja) * 1998-04-10 2001-04-03 Asahi Glass Co Ltd 球状シリカ粒子の製造方法
WO1999052870A1 (en) 1998-04-13 1999-10-21 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
AU3667899A (en) * 1998-04-29 1999-11-16 American Home Products Corporation Antipsychotic indolyl derivatives
JPH11335286A (ja) 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
HK1047548A1 (zh) 2000-01-19 2003-02-28 Akzo Nobel N.V. 包含有米氮平和哲比隆的治疗抑郁症及其它机能紊乱症的合成药物
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
EP1353675A2 (en) 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
EA009780B1 (ru) 2001-06-19 2008-04-28 Норберт Мюллер Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
US9125939B2 (en) 2003-05-23 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
KR100931784B1 (ko) 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
EA200970116A1 (ru) * 2006-07-12 2009-08-28 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Кристаллический гидрохлорид неморубицина
WO2009072334A1 (ja) 2007-12-03 2009-06-11 Tomita Pharmaceutical Co., Ltd. 製剤用核粒子
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament

Also Published As

Publication number Publication date
CN106420640A (zh) 2017-02-22
DE60236231D1 (de) 2010-06-10
ATE465737T1 (de) 2010-05-15
CN101574347B (zh) 2012-02-29
CN101434574A (zh) 2009-05-20
EP1419776A8 (en) 2004-09-01
DK1419776T4 (en) 2017-09-04
US20070213343A1 (en) 2007-09-13
CA2688934A1 (en) 2003-04-03
US8901303B2 (en) 2014-12-02
CN101574348A (zh) 2009-11-11
US20120316179A1 (en) 2012-12-13
AU2002334413C9 (en) 2015-04-09
EP1927357B1 (en) 2010-05-12
PT1330249E (pt) 2006-06-30
US20120000998A1 (en) 2012-01-05
US20120316180A1 (en) 2012-12-13
CA2688860A1 (en) 2003-04-03
EP1419776A3 (en) 2004-06-16
US8580796B2 (en) 2013-11-12
PT1927356E (pt) 2010-05-24
NO336264B1 (no) 2015-07-06
US20120016123A1 (en) 2012-01-19
ATE465736T1 (de) 2010-05-15
PT1927357E (pt) 2010-06-08
CA2426921A1 (en) 2003-04-03
CA2688934C (en) 2011-05-17
ES2261750T3 (es) 2006-11-16
SI1419776T1 (sl) 2010-07-30
US20150225347A1 (en) 2015-08-13
US20070212421A1 (en) 2007-09-13
NO328134B1 (no) 2009-12-14
US20070203150A1 (en) 2007-08-30
DE60235995D1 (de) 2010-05-27
CN1817882B (zh) 2011-09-07
JP4614870B2 (ja) 2011-01-19
US8901130B2 (en) 2014-12-02
US8399469B2 (en) 2013-03-19
US7910589B2 (en) 2011-03-22
HUP0600141A2 (hu) 2006-05-29
EP1925308B1 (en) 2016-08-31
CA2689052C (en) 2011-02-15
DK1927357T3 (da) 2010-08-16
DE60236229D1 (de) 2010-06-10
DK1419776T3 (da) 2010-07-05
CN101423492A (zh) 2009-05-06
SI1330249T1 (sl) 2006-10-31
DK1330249T3 (da) 2006-08-07
EP1330249B1 (en) 2006-04-05
SI1927355T1 (sl) 2010-07-30
EP1927355A1 (en) 2008-06-04
CN106692151A (zh) 2017-05-24
CN101579344A (zh) 2009-11-18
NO336679B1 (no) 2015-10-19
CN101423493A (zh) 2009-05-06
PL225415B1 (pl) 2017-04-28
DK1927355T3 (da) 2010-07-19
EP1927356A1 (en) 2008-06-04
NO336262B1 (no) 2015-07-06
US20140309236A1 (en) 2014-10-16
DE60210409D1 (de) 2006-05-18
NO20030247D0 (no) 2003-01-17
NO20081633L (no) 2003-01-17
NO336265B1 (no) 2015-07-06
BR0205391A (pt) 2003-07-29
CA2689051A1 (en) 2003-04-03
JP3750023B2 (ja) 2006-03-01
CA2688915C (en) 2011-02-01
EP1927357A2 (en) 2008-06-04
US8703773B2 (en) 2014-04-22
CN1817882A (zh) 2006-08-16
CN106420627A (zh) 2017-02-22
IL153838A (en) 2008-04-13
AU2002334413B2 (en) 2004-11-04
EP1927356B1 (en) 2010-04-28
CA2426921C (en) 2011-03-15
ATE467416T1 (de) 2010-05-15
CN101579343B (zh) 2012-04-18
CN101434573A (zh) 2009-05-20
US20070203152A1 (en) 2007-08-30
US8017615B2 (en) 2011-09-13
CA2688915A1 (en) 2003-04-03
US20070203151A1 (en) 2007-08-30
US8993761B2 (en) 2015-03-31
CA2689052A1 (en) 2003-04-03
EP1419776A9 (en) 2004-09-08
ES2343179T5 (es) 2017-10-19
EP1419776B1 (en) 2010-04-14
SI1419776T2 (sl) 2017-12-29
DK1927356T3 (da) 2010-07-26
CN101434573B (zh) 2011-12-07
NO20081631L (no) 2003-01-17
CY1118195T1 (el) 2017-06-28
CN1699346A (zh) 2005-11-23
AR056503A2 (es) 2007-10-10
PT1419776E (pt) 2010-04-28
ES2343602T3 (es) 2010-08-04
IL153838A0 (en) 2003-07-31
CN101579343A (zh) 2009-11-18
HUP0600141A3 (en) 2008-03-28
CN101423492B (zh) 2013-08-28
US20210395204A1 (en) 2021-12-23
NO20091689L (no) 2003-01-17
EP1927357A3 (en) 2008-06-11
EP1330249A1 (en) 2003-07-30
CN1463191A (zh) 2003-12-24
JP2003212852A (ja) 2003-07-30
UA84764C2 (en) 2008-11-25
US20040058935A1 (en) 2004-03-25
NO20081632L (no) 2003-01-17
CN101434574B (zh) 2011-12-14
AR033485A1 (es) 2003-12-26
JP3760264B2 (ja) 2006-03-29
NO20030247L (no) 2003-01-17
US9359302B2 (en) 2016-06-07
CN101434575A (zh) 2009-05-20
CN101792415A (zh) 2010-08-04
DE60236383D1 (de) 2010-06-24
US20070213344A1 (en) 2007-09-13
PE20090124A1 (es) 2009-03-07
ES2343220T3 (es) 2010-07-26
JP2004256555A (ja) 2004-09-16
US20160251315A1 (en) 2016-09-01
JP2006070045A (ja) 2006-03-16
ES2343219T3 (es) 2010-07-26
EP1419776B2 (en) 2017-07-19
EP1927355B1 (en) 2010-04-28
DE60210409T2 (de) 2006-11-16
AU2002334413C1 (en) 2021-08-12
NO20081626L (no) 2003-01-17
SI1927356T1 (sl) 2010-07-30
WO2003026659A1 (en) 2003-04-03
US20190225584A1 (en) 2019-07-25
IL188455A0 (en) 2008-03-20
CN101574348B (zh) 2012-02-22
NO336263B1 (no) 2015-07-06
CN101574347A (zh) 2009-11-11
US20070202181A1 (en) 2007-08-30
CA2689051C (en) 2011-03-08
US20200123110A1 (en) 2020-04-23
ATE464050T1 (de) 2010-04-15
US8642760B2 (en) 2014-02-04
ES2343179T3 (es) 2010-07-26
ATE322269T1 (de) 2006-04-15
US20120315302A1 (en) 2012-12-13
CN101579344B (zh) 2012-05-30
NO20081627L (no) 2003-01-17
MXPA03000440A (es) 2003-10-06
EP1925308A1 (en) 2008-05-28
EP1419776A2 (en) 2004-05-19
PT1927355E (pt) 2010-06-11
US20140030523A1 (en) 2014-01-30
US10150735B2 (en) 2018-12-11

Similar Documents

Publication Publication Date Title
PL360900A1 (pl) Niskohigroskopijna substancja lecznicza na bazie aripiprazolu i sposoby jej wytwarzania
YU69603A (sh) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
NZ504017A (en) Preparation of gatifloxacin and disodium edetate
IL149681A0 (en) Polymorphic form of atorvstatin calcium
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
HUP0303810A3 (en) Carboxylic acid derivative and salt thereof and pharmaceutical compositions containing them
EP1246608A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
HUP0000979A1 (hu) FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények
DE60036014D1 (de) Methode zur stabilisierung von benzimidazol-verbindungen
SI1441769T1 (sl) Farmacevtske formulacije, ki vsebujejo nizke koncentracije peroksida, za zdravljenje ali preprecevanje vaginalnih infekcij
PH12014500782A1 (en) Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
UA80802C2 (en) Low hygroscopic aripiprazole drug substance and process for the preparation thereof
DE69104220D1 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
PL368040A1 (pl) Podstawione pochodne 4-aminocykloheksanolu
HUP0400925A3 (en) Azolycarbynol derivatives of aryl (or heteroaryl) for producing pharmaceutical compositions for the treatment of respiratory diseases
GEP20053457B (en) Low Hygroscopic Aripiprazole Drug Substance and Processes for Preparation Thereof
NO992513L (no) Krystaller av antimikrobielle forbindelser i anhydratform og anvendelse og farmas°ytiske preparater derav
EP1541144A4 (en) INDOMETHACINE PREPARATION FOR TOPICAL APPLICATION
MY138319A (en) 1,5-benzodiazepine derivatives
BG103923A (en) Sulphate salt of hiv protease inhibitor with improved peroral absorption and biopresence
PL357568A1 (pl) Nowe pochodne pirazyny lub ich sole, zawierająca je kompozycja farmaceutyczna i sposób wytwarzania ich związków pośrednich

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 393596

Country of ref document: PL

Kind code of ref document: A1